Enzo Biochem (NYSE:ENZ) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Enzo Biochem and Celcuity, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Enzo Biochem | 0 | 0 | 0 | 0 | N/A |
Celcuity | 0 | 0 | 2 | 0 | 3.00 |
Celcuity has a consensus target price of $27.00, indicating a potential upside of 8.70%. Given Celcuity's higher probable upside, analysts clearly believe Celcuity is more favorable than Enzo Biochem.
Profitability
This table compares Enzo Biochem and Celcuity's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Enzo Biochem | -24.36% | -27.05% | -14.76% |
Celcuity | N/A | -52.57% | -49.69% |
Insider and Institutional Ownership
60.4% of Enzo Biochem shares are owned by institutional investors. Comparatively, 18.6% of Celcuity shares are owned by institutional investors. 9.4% of Enzo Biochem shares are owned by company insiders. Comparatively, 43.5% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Enzo Biochem and Celcuity's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Enzo Biochem | $76.02 million | 2.13 | $-28,520,000.00 | N/A | N/A |
Celcuity | N/A | N/A | $-7,360,000.00 | ($0.72) | -34.50 |
Celcuity has lower revenue, but higher earnings than Enzo Biochem.
Risk & Volatility
Enzo Biochem has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.
Summary
Celcuity beats Enzo Biochem on 6 of the 11 factors compared between the two stocks.